You remember Medable, you won’t recognize our eCOA
While you’ve been away, we’ve rebuilt eCOA from study setup to the participant experience. Studio, AI, and automation make it easier to launch studies, manage changes, and keep participants on track with results from global studies to back it up.
We handle the complexity, you keep control
Complex protocols shouldn’t create complex operations. Medable absorbs more of the complexity behind eCOA so study teams can move faster while maintaining control and regulatory quality.
Start sooner and keep studies on track
Build and launch globally, faster
AI-powered design, translation, validation, and deployment now run in parallel, enabling near-simultaneous multi-country deployment.
Change without the chaos
Handle protocol amendments, cohort changes, and other mid-study updates without turning every change into a major rebuild.
Keep the data coming
Real-time data and dashboards help teams spot missed entries, while notifications and reminders keep participants on track, with daily diary adherence of 90–97% demonstrated across global studies.
See how far eCOA has come
Your next study deserves more than legacy eCOA. Before you go with the familiar, see what you could be missing.
Old eCOA model
Medable eCOA model
When it comes to modern eCOA solutions Medable is leading the pack.
Results with top customers at programmatic scale
faster builds compared with legacy eCOA
participant adherence across studies
accommodated on one global program
A lot has changed since you last used Medable
- Agentic instrument configuration
- AI-powered translation
- AI-assisted pre-testing and quality engineering
- Data on demand
- Standardized deployment
- Agentic PI summarization
- Episodic diaries and caregiver observers
- Intelligent consent
The latest ecoa case studies
A results-focused look at cardiometabolic trials at Medable
With GLP-1 therapies reshaping the competitive landscape, sponsors need speed to first patient, portfolio consistency, and adherence that holds up over years, not weeks. See how five sponsors/CROs got there with Medable.
Case study: Scaling global vaccine mega-trials for a top-5 pharma
Learn how Medable enabled a top-5 pharma to scale vaccine mega-trials with near-100% enrollment, real-time safety data, and >90% diary compliance.
Case study: ICON and Medable drive 85% eConsent adoption in U.S. menopause study
How do you drive adoption in a complex women’s health study? See how ICON and Medable reached 85% eConsent uptake across 1,200+ participants with a smarter, site-first approach.